IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,418,934 | -35.4% | 4,707,458 | 0.0% | 0.46% | -24.2% |
| Q2 2023 | $33,140,504 | +15.2% | 4,707,458 | 0.0% | 0.60% | +6.2% |
| Q1 2023 | $28,762,568 | +124.2% | 4,707,458 | +134.5% | 0.56% | +130.6% |
| Q4 2022 | $12,827,657 | -33.3% | 2,007,458 | 0.0% | 0.24% | -31.4% |
| Q3 2022 | $19,231,000 | -37.8% | 2,007,458 | -28.3% | 0.36% | -36.2% |
| Q2 2022 | $30,895,000 | -72.0% | 2,798,441 | -57.8% | 0.56% | -68.7% |
| Q1 2022 | $110,440,000 | -8.7% | 6,633,006 | +4.7% | 1.79% | +15.2% |
| Q4 2021 | $120,987,000 | -26.2% | 6,337,700 | -4.6% | 1.56% | -13.7% |
| Q3 2021 | $163,868,000 | -5.2% | 6,645,100 | 0.0% | 1.80% | +3.0% |
| Q2 2021 | $172,906,000 | -17.8% | 6,645,100 | 0.0% | 1.75% | -11.1% |
| Q1 2021 | $210,384,000 | -31.8% | 6,645,100 | 0.0% | 1.97% | -27.1% |
| Q4 2020 | $308,333,000 | +40.9% | 6,645,100 | 0.0% | 2.70% | -1.9% |
| Q3 2020 | $218,757,000 | +19.9% | 6,645,100 | 0.0% | 2.75% | +7.1% |
| Q2 2020 | $182,408,000 | +9.8% | 6,645,100 | +19.8% | 2.57% | -8.0% |
| Q1 2020 | $166,089,000 | +8.1% | 5,548,326 | 0.0% | 2.79% | +27.3% |
| Q4 2019 | $153,578,000 | +52.1% | 5,548,326 | 0.0% | 2.19% | +14.5% |
| Q3 2019 | $100,980,000 | -25.8% | 5,548,326 | 0.0% | 1.92% | -9.1% |
| Q2 2019 | $136,045,000 | +157.8% | 5,548,326 | 0.0% | 2.11% | +157.9% |
| Q1 2019 | $52,765,000 | +7.5% | 5,548,326 | 0.0% | 0.82% | -10.0% |
| Q4 2018 | $49,103,000 | -21.3% | 5,548,326 | 0.0% | 0.91% | +20.7% |
| Q3 2018 | $62,419,000 | -12.1% | 5,548,326 | 0.0% | 0.75% | -11.2% |
| Q2 2018 | $71,019,000 | -24.3% | 5,548,326 | 0.0% | 0.85% | -27.2% |
| Q1 2018 | $93,767,000 | +111.2% | 5,548,326 | 0.0% | 1.16% | +107.3% |
| Q4 2017 | $44,387,000 | -10.9% | 5,548,326 | -13.7% | 0.56% | +17.9% |
| Q3 2017 | $49,799,000 | +97.6% | 6,425,626 | +89.9% | 0.48% | +80.3% |
| Q2 2017 | $25,203,000 | – | 3,382,900 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |